BioPharma Credit PLC USD · LSE:BPCP

BioPharma Credit PLC USD — BioPharma Credit — Investor Presentation (September 2019)

15 slides from BioPharma Credit PLC USD's investor presentation, September 2019

  1. Slide 1: Debt Capital for the Life Sciences Industry

    Debt Capital for the Life Sciences Industry COMPANY PRESENTATION – September 2019 For additional information please email: ir@bpcruk.com or visit BioPharma Credit’s website at www.bpcruk.com

  2. Slide 2: Disclaimer

    Disclaimer . THIS PRESENTATION IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION. THIS PRESENTATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDIC

  3. Slide 3: Disclaimer

    Disclaimer This presentation was prepared using the financial information available to the Company as at the date of this presentation. Except where otherwise indicated herein, the information provided in this presentation is based on matters as they exist as of the date of preparation and not as of

  4. Slide 4: Financial Highlights

    Financial Highlights1 1 Excerpt from the Company’s Half-Yearly Report for the period ended 30 June 2019. 3

  5. Slide 5: Financial Highlights

    Financial Highlights1 1 Excerpt from the Company’s Half-Yearly Report for the period ended 30 June 2019. 4

  6. Slide 6: Portfolio and Dividends since IPO

    Portfolio and Dividends since IPO2 Evolution of the BioPharma Credit portfolio (millions) BPCR Portfolio Composition ($m) $1,600 • ~ $339m or 100% of seed assets Cash (RPS + BP-III) have amortized $21 $1,400 RPS since IPO $83 $150 $1,200 $150 BioPharma III • ~$1,100m deployed across nine $64 $103 ne

  7. Slide 7: Major milestones since IPO

    Major milestones since IPO1 Total Raised for BPCR2 IPO – $762m gross Placing of Ordinary Issue of C- Placing of Ordinary ~$1,385m gross proceeds including Shares – $154m Shares – Shares – $305m proceeds $339m of seed gross proceeds $163m gross gross proceeds assets proceeds ($1,045m in cash) March 2

  8. Slide 8: The majority of new drugs approved originated at smaller biopharma companies

    The majority of new drugs approved originated at, or were initially developed by, smaller biopharma companies 7 Source: Pharmakon Advisors

  9. Slide 9: Summary of Past Transactions

    Summary of Past Transactions 8

  10. Slide 10: $25m equity plus up to $80m senior secured corporate loan to BioDelivery Sciences

    $25m equity plus up to $80m senior secured corporate loan to BioDelivery Sciences BioDelivery Sciences Corporate Overview Description of key products  Description: BioDelivery Sciences International, Inc. (”BDSI") is a  BELBUCA (buprenorphine buccal film) – approved in October 2015 specialty pharm

  11. Slide 11: $150m senior secured corporate loan to Amicus Therapeutics

    $150m senior secured corporate loan to Amicus Therapeutics Amicus Corporate Overview Key Products  Description: Amicus Therapeutics, Inc. (FOLD) is a biopharmaceutical  Fabry disease is a rare, progressive genetic disorder characterized by a company focused on orphan diseases. Amicus markets Galaf

  12. Slide 12: $316m senior secured corporate loan to help finance Sebela's acquisition of Braintree Laboratories

    $316m senior secured corporate loan to help finance Sebela’s acquisition of Braintree Laboratories Sebela Corporate Overview Key Products  Description: Sebela Pharmaceuticals is a privately-held US  Suprep – osmotic laxative indicated for cleansing of the colon focused specialty pharmaceutical com

  13. Slide 13: $150m senior secured corporate loan to Novocure

    $150m senior secured corporate loan to Novocure Novocure Corporate Overview Key Products  Description: Novocure is a commercial stage oncology company  Optune System – a cancer treatment centered on a proprietary developing a profoundly different cancer treatment utilizing a therapy called TTField

  14. Slide 14: $140m-$160m purchase and sale agreement with Bristol Myers Squibb

    $140m-$160m purchase and sale agreement with Bristol Myers Squibb Transaction Overview Key Products  Description: On 8 December 2017, a wholly-owned subsidiary of  FARXIGA (dapagliflozin) – a sodium-glucose cotransporter 2 BPCR entered into a purchase, sale and assignment agreement with (SGLT2) in

  15. Slide 15: $150m senior secured loan to Lexicon

    $150m senior secured loan to Lexicon Lexicon Corporate Overview Key Products  Description: Lexicon Pharmaceuticals, Inc. (LXRX) is a  XERMELO (telotristat ethyl) - an oral treatment that works with biopharmaceutical company focused on developing drugs for cancer, somatostatin analog (SSA) therapy

BioPharma Credit — Investor Presentation (September 2019) on 6ix